References
- Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov 2015; 14:261-78; PMID:25743081; http://dx.doi.org/10.1038/nrd4505
- De Gassart A, Demaria O, Panes R, Zaffalon L, Ryazanov AG, Gilliet M, Martinon F. Pharmacological eEF2K activation promotes cell death and inhibits cancer progression. EMBO Rep 2016; 17:1471-84; PMID:27572820; http://dx.doi.org/10.15252/embr.201642194
- Koltai T. Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs. F1000Res 2015; 4:9; PMID:26097685; http://dx.doi.org/10.12688/f1000research.6789.1
- De Gassart A, Bujisic B, Zaffalon L, Decosterd LA, Di Micco A, Frera G, Tallant R, Martinon F. An inhibitor of HIV-1 protease modulates constitutive eIF2a dephosphorylation to trigger a specific integrated stress response. Proc Natl Acad Sci U S A 2016; 113:E117-26; PMID:26715744; http://dx.doi.org/10.1073/pnas.1514076113
- Kenney JW, Moore CE, Wang X, Proud CG. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. Adv Biol Regul 2014; 55:15-27; PMID:24853390; http://dx.doi.org/10.1016/j.jbior.2014.04.003
- Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo A-RF, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013; 153:1064-79; PMID:23706743; http://dx.doi.org/10.1016/j.cell.2013.04.055
- Faller WJ, Jackson TJ, Knight JRP, Ridgway RA, Jamieson T, Karim SA, Jones C, Radulescu S, Huels DJ, Myant KB, et al. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 2015; 517:497-500; PMID:25383520; http://dx.doi.org/10.1038/nature13896